Which has better earnings and valuation, AMGN or AZN?

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $38.10B 5.92 $7.71B $16.09 25.92 Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31

Is AMGN or AZN more profitable?

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Astrazeneca 17.02% 31.45% 13.20%

Does the media favor AMGN or AZN?

In the previous week, Amgen had 23 more articles in the media than Astrazeneca. MarketBeat recorded 38 mentions for Amgen and 15 mentions for Astrazeneca. Amgen's average media sentiment score of 1.21 beat Astrazeneca's score of 0.38 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 31 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, AZN or BIIB?

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31 Biogen $10.03B 3.08 $1.29B $5.65 37.06

Is AZN or BIIB more profitable?

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Biogen 8.32% 11.18% 6.88%

Does the media refer more to AZN or BIIB?

In the previous week, Astrazeneca had 5 more articles in the media than Biogen. MarketBeat recorded 15 mentions for Astrazeneca and 10 mentions for Biogen. Biogen's average media sentiment score of 1.29 beat Astrazeneca's score of 0.38 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AZN or MRNA?

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31 Moderna $1.94B 13.40 -$2.82B -$7.99 N/A

Is AZN or MRNA more profitable?

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Moderna -141.43% -28.30% -19.39%

Does the media favor AZN or MRNA?

In the previous week, Astrazeneca had 7 more articles in the media than Moderna. MarketBeat recorded 15 mentions for Astrazeneca and 8 mentions for Moderna. Moderna's average media sentiment score of 0.54 beat Astrazeneca's score of 0.38 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Moderna 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31 Novavax $1.12B 1.19 $440.30M -$1.52 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Novavax -59.87% -14.82% -13.35%

Does the media prefer AZN or NVAX?

In the previous week, Astrazeneca had 11 more articles in the media than Novavax. MarketBeat recorded 15 mentions for Astrazeneca and 4 mentions for Novavax. Novavax's average media sentiment score of 1.09 beat Astrazeneca's score of 0.38 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Novavax 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $64.39B 6.87 $4.23B $3.54 70.68 Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to ABBV or AZN?

In the previous week, AbbVie had 41 more articles in the media than Astrazeneca. MarketBeat recorded 56 mentions for AbbVie and 15 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.18 beat Astrazeneca's score of 0.38 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 38 Very Positive mention(s) 9 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Astrazeneca (AZN) Competitors

$156.08 -0.37 (-0.23%)

As of 01:25 PM Eastern

Compare

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? Astrazeneca's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Astrazeneca compare to Amgen?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Astrazeneca	17.02%	31.45%	13.20%

Amgen presently has a consensus target price of $372.39, suggesting a potential downside of 10.71%. Astrazeneca has a consensus target price of $211.00, suggesting a potential upside of 35.28%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.35
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Amgen pays out 62.6% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Amgen had 23 more articles in the media than Astrazeneca. MarketBeat recorded 38 mentions for Amgen and 15 mentions for Astrazeneca. Amgen's average media sentiment score of 1.21 beat Astrazeneca's score of 0.38 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	31 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$38.10B	5.92	$7.71B	$16.09	25.92
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31

Summary

Amgen beats Astrazeneca on 13 of the 19 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Astrazeneca (NYSE:AZN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, Astrazeneca had 5 more articles in the media than Biogen. MarketBeat recorded 15 mentions for Astrazeneca and 10 mentions for Biogen. Biogen's average media sentiment score of 1.29 beat Astrazeneca's score of 0.38 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca currently has a consensus price target of $211.00, suggesting a potential upside of 35.28%. Biogen has a consensus price target of $227.07, suggesting a potential upside of 8.46%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31
Biogen	$10.03B	3.08	$1.29B	$5.65	37.06

Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Biogen	8.32%	11.18%	6.88%

Summary

Astrazeneca beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Astrazeneca (NYSE:AZN) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 35.28%. Moderna has a consensus target price of $42.13, indicating a potential downside of 35.42%. Given Astrazeneca's stronger consensus rating and higher probable upside, research analysts plainly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Moderna	-141.43%	-28.30%	-19.39%

In the previous week, Astrazeneca had 7 more articles in the media than Moderna. MarketBeat recorded 15 mentions for Astrazeneca and 8 mentions for Moderna. Moderna's average media sentiment score of 0.54 beat Astrazeneca's score of 0.38 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31
Moderna	$1.94B	13.40	-$2.82B	-$7.99	N/A

Summary

Astrazeneca beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Astrazeneca presently has a consensus target price of $211.00, suggesting a potential upside of 35.28%. Novavax has a consensus target price of $13.00, suggesting a potential upside of 60.00%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31
Novavax	$1.12B	1.19	$440.30M	-$1.52	N/A

Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Novavax has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market.

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novavax	-59.87%	-14.82%	-13.35%

In the previous week, Astrazeneca had 11 more articles in the media than Novavax. MarketBeat recorded 15 mentions for Astrazeneca and 4 mentions for Novavax. Novavax's average media sentiment score of 1.09 beat Astrazeneca's score of 0.38 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Astrazeneca beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

AbbVie has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

In the previous week, AbbVie had 41 more articles in the media than Astrazeneca. MarketBeat recorded 56 mentions for AbbVie and 15 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.18 beat Astrazeneca's score of 0.38 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	38 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Astrazeneca	17.02%	31.45%	13.20%

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	6.87	$4.23B	$3.54	70.68
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31

AbbVie currently has a consensus price target of $275.73, indicating a potential upside of 10.20%. Astrazeneca has a consensus price target of $211.00, indicating a potential upside of 35.28%. Given Astrazeneca's higher possible upside, analysts plainly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$241.99B	$11.88B	$7.02B	$24.26B
Dividend Yield	2.77%	2.69%	2.56%	3.67%
P/E Ratio	23.32	782.06	271.65	30.63
Price / Sales	4.12	752.71	604.23	20.22
Price / Cash	12.10	15.03	28.87	20.48
Price / Book	4.97	10.36	11.07	4.93
Net Income	$10.23B	$2.79B	$3.45B	$1.07B
7 Day Performance	-3.60%	0.32%	0.96%	0.40%
1 Month Performance	-7.61%	0.19%	2.33%	2.76%
1 Year Performance	N/A	145.94%	63.28%	18.94%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	4.9004 of 5 stars	$156.08 -0.2%	$211.00 +35.2%	N/A	$242.07B	$58.74B	23.33	96,100
AMGN Amgen	3.8626 of 5 stars	$415.21 -0.6%	$372.39 -10.3%	+40.1%	$224.48B	$38.10B	25.81	31,500	Positive News Analyst Forecast
BIIB Biogen	4.0578 of 5 stars	$209.83 -0.4%	$227.07 +8.2%	+51.4%	$31.00B	$10.03B	37.14	7,500	Positive News
MRNA Moderna	1.2459 of 5 stars	$63.32 -0.5%	$42.13 -33.5%	+126.0%	$25.28B	$1.94B	N/A	4,700	Gap Up
NVAX Novavax	1.7494 of 5 stars	$8.05 -1.1%	$13.00 +61.5%	-16.0%	$1.33B	$1.12B	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors